JAMA Oncology
Comment & Response
April 11, 2024
Yongwoo DavidÌýSeo,ÌýMD; Seth M.ÌýPollack,ÌýMD
online first
JAMA Oncol. 2024; 10.1001/jamaoncol.2024.0311
JAMA Oncology
Original Investigation
October 12, 2023
Yongwoo DavidÌýSeo,ÌýMD; HailingÌýLu,ÌýMD, PhD; GraemeÌýBlack,ÌýBS; KimberlyÌýSmythe,ÌýBS; YuexinÌýYu,ÌýPhD; CynthiaÌýHsu,ÌýBS; JulianaÌýNg,ÌýBS; PedroÌýHermida de Viveiros,ÌýMD; E. HoustonÌýWarren,ÌýMD, PhD; Brett A.ÌýSchroeder,ÌýMD; Ryan B.ÌýO’Malley,ÌýMD; Lee D.ÌýCranmer,ÌýMD, PhD; Elizabeth T.ÌýLoggers,ÌýMD, PhD; Michael J.ÌýWagner,ÌýMD; LynnÌýBonham,ÌýPhD; Venu G.ÌýPillarisetty,ÌýMD; GabrielleÌýKane,ÌýMD; PeterÌýBerglund,ÌýPhD; Frank J.ÌýHsu,ÌýMD; XinleiÌýMi,ÌýPhD; Borislav A.ÌýAlexiev,ÌýMD; Robert H.ÌýPierce,ÌýMD; Stanley R.ÌýRiddell,ÌýMD; Robin L.ÌýJones,ÌýMD; JanÌýter Meulen,ÌýMD, PhD; Edward Y.ÌýKim,ÌýMD; Seth M.ÌýPollack,ÌýMD
open access
JAMA Oncol. 2023; 9(12):1660-1668. 10.1001/jamaoncol.2023.4015
This nonrandomized controlled trial of patients with advanced soft tissue sarcoma analyzed the immunomodulatory effects of intratumoral glycopyranosyl lipid A in stable-emulsion formulation with concurrent radiotherapy.